Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

AbbVie’s Produodopa® (foslevodopa-foscarbidopa) Accepted by Scottish Medicines Consortium as Treatment Option for Advanced Levodopa-Responsive Parkinson’s Disease

For Medical and Trade media. · Foslevodopa-foscarbidopa will soon be available for eligible patients with advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia in Scotland, providing an additional option when currently available combinations of treatments have not given satisfactory results[1] · Following the recommendation by the National Institute for Health and Care Excellence (NICE) in November 2023, this means foslevodopa-foscarbidopa will soon be available for use within the NHS across the UK[2] · The advice from the

Notice of Annual General Meeting in Sleep Cycle AB (publ)

The shareholders of Sleep Cycle AB (publ) (“Sleep Cycle”), reg. no. 556614-7368, are hereby invited to attend the Annual General Meeting (the “AGM”) to be held on 11 April 2024 at 09:30 CEST at Jacy’z hotel, floor 24, Drakegatan 10, 412 50 Gothenburg, Sweden. Admission and registration for the AGM will begin at 09:00 CEST.The Board of Directors has resolved, in accordance with the provisions of Sleep Cycle’s Articles of Association, that shareholders may also exercise their voting rights in advance by so-called postal voting. Right to participate and notification A) Attending the

Sivers Semiconductors announces an expanded loan facility of SEK 50 million

With this financing, the Company has secured funding for continued growthKista, Sweden // Mar. 11, 2024 // Sivers Semiconductors AB (STO: SIVE), (the "Company"), a leading supplier of integrated chips and modules for the most advanced communications and sensor solutions, has, according to previous communication in connection with the 2023 fourth-quarter report, agreed to entered into a loan agreement with Formue Nord and partners extending the previous SEK 75 million facility. The new SEK 50 million loan facility includes a SEK 35 million convertible loan at a fixed conversion rate of 4.86

Gaming Innovation Group - Mandatory notification of trade

Mikael Riese Harstad, board member and primary insider of Gaming Innovation Group Inc. (GiG), has today transferred 477,733 shares in GiG without consideration to his wife Helena Riese Harstad. This transaction will not change the number of shares held by Harstad and close associates, and after this transaction, Harstad and close associates owns 1,342,136 shares in GiG. For further information, contact: Tore Formo, Group CFO, tore@gig.com +47 916 68 678 This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Spinomenal Enhances 888 Collaboration with Italian Expansion

Spinomenal, the leading iGaming content provider, has amplified its Italian iGaming presence thanks to a new content partnership with 888 Italy. Spinomenal’s titles are being integrated via Pariplay’s aggregation platform, Fusion.Spinomenal made its debut in the Italian market in the summer and it has become an important region for the business. Players using 888 Italy will be able to enjoy a wide selection of games, including the hugely popular Majestic King, Book of Demi Gods 2, Egyptian Rebirth and many others.Italy joins the list of already established markets, including UK, Romania,

ColdZyme® certified under the new EU medical device regulation (MDR)

Enzymatica’s mouth spray ColdZyme® has received CE-certification under the new and more demanding European Union medical device regulation (MDR). This important milestone validates the company’s scientific data and extends product claims throughout the EU. The certification is a key pillar for expansion in several markets and is expected to have long-term positive effects on Enzymatica’s growth. Eurofins, a European approved notified body for medical devices, has certified the ColdZyme® product line MDR (class III) according to the European Union medical device regulation. MDR replaces

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BR0WHY71 Issuer Name ACUITY RM GROUP PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Jonathan Mark Swann City of registered office (if applicable) rickmansworth Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification

Inside information: Outokumpu downgrades its guidance for Q1 2024 – adjusted EBITDA expected to be at a similar or lower level compared to Q4 2023 due to the political strike in Finland

Outokumpu OyjInside informationMarch 11, 2024 at 12.15 pm EETInside information: Outokumpu downgrades its guidance for Q1 2024 – adjusted EBITDA expected to be at a similar or lower level compared to Q4 2023 due to the political strike in Finland Outokumpu downgrades its guidance for the first quarter of 2024 due to the political strike in Finland. The political strike is aimed against the Finnish government and is not related to Outokumpu’s labor relations. Majority of Outokumpu’s stainless steel and ferrochrome operations as well as Tornio port in Finland will be shut down for

Acquisitions of own shares in Evolution AB (publ)

Evolution AB (publ) (“Evolution”) has, during the period 04 March – 08 March acquired a total of 259,324 own shares within the framework of the repurchase programme introduced by the board of directors to improve the capital structure of Evolution by reducing the capital, and thereby creating added shareholder value.The repurchase programme, which Evolution announced on 23 November 2023, is being implemented in accordance with the EU Market Abuse Regulation No 596/2014 (“MAR”) and Commission Delegated Regulation No 2016/1052 (“Safe Harbour Regulation”). During the period 04 March – 08

Nordic Mining ASA: Key information relating to the reverse split and change of ISIN

Key information relating to the reverse split resolved by the Extraordinary General Meeting on 11 March 2024:   Date on which the terms and conditions of the share consolidation was made public: 19 February 2024 Reverse split ratio: 20 old shares give 1 new share Last day including right: 12 March 2024 Ex-date: 13 March 2024 Record date: 14 March 2024 Date of approval: 11 March 2024   In connection with the share consolidation, the Company's shares will be transferred to a new ISIN. Please find below the following key information for the change of ISIN: Issuer:

Nordic Mining ASA: Reverse split resolved by the Extraordinary General Meeting

The Extraordinary General Meeting in Nordic Mining ASA was held Monday 11 March 2024. All agenda items were approved in line with the proposals in the Extraordinary General Meeting notice. See separate press release with key information relating to the reverse split resolved by the Extraordinary General Meeting. The minutes from the Extraordinary General Meeting in Norwegian and English are attached. For further information, please contact CFO Jens Gisle Schnelle, telephone +47 476 60 355 Oslo, 11 March 2024Nordic Mining ASA This information is subject to the disclosure

Terveystalo Plc - Managers' transactions - Saviharju

Terveystalo Plc, Managers' transactions, 11 March 2024 at 11:48 a.m. EET This is a notification under the Market Abuse Regulation (MAR) that General Counsel Elina Saviharju has received shares in Terveystalo as part of the performance share plan 2021-2023. Person subject to the notification requirementName: Saviharju, ElinaPosition: Other senior managerIssuer: Terveystalo PlcLEI: 7437001AEZHLL3UEX093 Notification type: INITIAL NOTIFICATIONReference number: 7437001AEZHLL3UEX093_20240308135126_60____________________________________________ Transaction date: 2024-03-07

Terveystalo Plc - Managers' transactions - Mäenalanen

Terveystalo Plc, Managers' transactions, 11 March 2024 at 11:47 a.m. EET This is a notification under the Market Abuse Regulation (MAR) that EVP Henri Mäenalanen has received shares in Terveystalo as part of the performance share plan 2021-2023. Person subject to the notification requirementName: Mäenalanen, HenriPosition: Other senior managerIssuer: Terveystalo PlcLEI: 7437001AEZHLL3UEX093 Notification type: INITIAL NOTIFICATIONReference number: 7437001AEZHLL3UEX093_20240308135126_58____________________________________________ Transaction date: 2024-03-07Venue not

Terveystalo Plc - Managers' transactions - Pajunen

Terveystalo Plc, Managers' transactions, 11 March 2024 at 11:46 a.m. EET This is a notification under the Market Abuse Regulation (MAR) that CFO Juuso Pajunen has received shares in Terveystalo as part of the performance share plan 2021-2023. Person subject to the notification requirementName: Pajunen, JuusoPosition: Chief Financial OfficerIssuer: Terveystalo PlcLEI: 7437001AEZHLL3UEX093 Notification type: INITIAL NOTIFICATIONReference number: 7437001AEZHLL3UEX093_20240308135126_59____________________________________________ Transaction date: 2024-03-07Venue not

Terveystalo Plc - Managers' transactions - Iho

Terveystalo Plc, Managers' transactions, 11 March 2024 at 11:45 a.m. EET This is a notification under the Market Abuse Regulation (MAR) that President and CEO Ville Iho has received shares in Terveystalo as part of the performance share plan 2021-2023. Person subject to the notification requirementName: Iho, VillePosition: Chief Executive OfficerIssuer: Terveystalo PlcLEI: 7437001AEZHLL3UEX093 Notification type: INITIAL NOTIFICATIONReference number: 7437001AEZHLL3UEX093_20240308135126_57____________________________________________ Transaction date: 2024-03-07Venue

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 58 – 11 MARTS 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 30/24 and 31/24.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Communications & Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Dampskibsselskabet NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 57 – 11 MARCH 2024 On 8 February 2024, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 9 February 2024 up to and including no later than 19 April 2024. For details, please see announcement no. 30 of 8 February 2024.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 15 million (approximately DKK 105 million).

YIT selected as service provider for the excavation contract of Espoo City Rail

YIT Corporation Press Release 11 March 2024 at 11.30 a.m.The Finnish Transport Infrastructure Agency and YIT Infra Oy have signed an agreement on the implementation of the excavation contract for the Espoo City Rail. The preparatory work for the contract will start in the coming days and the actual construction work in the contract area will start in April 2024. The work is expected to be completed by the end of September 2026. The total value of the excavation contract is approximately EUR 13 million and it will be recorded in the order book for the first quarter of 2024. In addition,

PVC-free resilient floors can be recycled! Installation waste from Kährs’ PVC-free products becomes new floors

Kährs has shown that it is possible to recycle PVC-free floors and reuse the material by using installation waste from its flooring products Zero Sheet, Zero & Green and Xpression. Since 2010, Kährs has recycled production waste from its PVC-free resilient floors, and last year the program was expanded to include recirculation of installation waste. Important steps in a circular direction. Saving the earth's resources by reusing and recycling as much material as possible is important for our society, the flooring industry and Kährs. Since 2010, Kährs has recycled waste material from

Save the date March 26 – Invitation to Munters Investor Relations webinar focused on Data Center Technologies

Welcome to Munters webinar focused on Data Center Technologies (DCT), a prioritized growth area for Munters. The webinar will provide an overview of the market as well as Munters strategy and operations. Participants: Munters CEO & President, Klas Forsström, GVP & President Data Center Technologies, Stefan Aspman and other experts within DCT. The webcast will start at 15:00 CET (14:00 GMT in London and 10:00 EDT in New York) on March 26, 2024, and is expected to conclude at 15:45 CET. The event will be webcast live and will also be available for viewing after the event on Munters

Sleep Cycle’s nomination committee proposes Hans Skruvfors as new member of the board of directors

Göteborg 11 March 2024 - The nomination committee has resolved to propose that Hans Skruvfors be elected new member of the Sleep Cycle AB board of directors at the annual general meeting on April 11, 2024. The addition of Hans Skruvfors marks another strategic move in the company’s efforts to sharpen its commercial focus.Hans Skruvfors has 20 years’ experience from leading positions in global consumer and tech brands. He is currently serving as CEO of Foodora (SE, DK, NO, FI), and during his tenure the company has finally achieved profitable growth in the Nordic market. Further, Hans serves

Prostatype Genomics publishes newsletter on US progress and the long-term follow-up study in Uppsala

Prostatype Genomics today publishes a newsletter for January–February 2024 with a CEO interview on what the three recently published advances in the United States mean for the company from an investor perspective, as well as an in-depth interview about the ongoing long-term follow-up study with Prostatype®, the company's gene test for prostate cancer patients, at Uppsala University Hospital.CEO Fredrik Persson explains the significance of the recently achieved milestones on the way to the US marketFredrik explains the significance of the three milestones achieved in the United States in

There are no items matching the current filter
There are no more items matching the current filter
Back to top